1. Home
  2. DCOY vs GNPX Comparison

DCOY vs GNPX Comparison

Compare DCOY & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$0.91

Market Cap

5.8M

Sector

Health Care

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$3.00

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCOY
GNPX
Founded
N/A
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8M
5.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
DCOY
GNPX
Price
$0.91
$3.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.2M
988.0K
Earning Date
03-23-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$1.71
52 Week High
$52.95
$55.00

Technical Indicators

Market Signals
Indicator
DCOY
GNPX
Relative Strength Index (RSI) N/A 59.18
Support Level N/A $2.10
Resistance Level N/A $3.56
Average True Range (ATR) 0.00 0.34
MACD 0.00 0.20
Stochastic Oscillator 0.00 69.19

Price Performance

Historical Comparison
DCOY
GNPX

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: